Browse treatments

…flammation (screening blood eosinophil counts ≥300 cells/µL) on triple therapy. Patients received add-on dupilumab or placebo for 52 weeks. En…

…e 2 inflammation (screening blood eosinophils ≥300 cells/µL) on triple therapy. Patients received add-on subcutaneous dupilumab 300 mg or matc…

…n: males p=0.07; females p=0.99. In female participants, use of hormonal contraception was associated with higher asthma prevalence when compared to n…

…d in those without asthma after addressing treatable traits and ICS cessation/reduction (baseline ACT: 18[14–23] and post-ICS reduc…

…ably, Type 2 (T2)-high patients may remain breathless even when biologic therapy successfully controls inflammatory biomarkers. In the Type-2 bi…

…b. Eight patients retained good asthma control whilst receiving dual Mab therapy, with one patient stopping mepolizumab at 12 months due to poor…

…orrelation coefficient [ICC]>0.90). Three participants received TB treatment during the study period for incident TB; in two, TB was microbi…

…tacts were prospectively followed for 2 years without receiving chemoprophylaxis. Monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte r…

…buted to the confirmation or exclusion of diagnoses amenable to steroid-responsive treatment. Although BAL cellularity aided early decision making regarding…

… cough hypersensitivity but are otherwise poorly characterized. Speech therapy treatment has been shown to be an effective treatment and assessment with…

…ortionately high impact on quality of life. Despite advances in biologic therapies, patients still face significant daily burdens. Little is known…

…atory system. PCD currently has no cure and is managed by daily chest physiotherapy and frequent hospital appointments with varying specialties. Pa…